Literature DB >> 7476918

Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions.

M Kotani1, I Tanaka, Y Ogawa, T Usui, K Mori, A Ichikawa, S Narumiya, T Yoshimi, K Nakao.   

Abstract

Five distinct cDNA clones encoding four different isoforms of human prostaglandin (PG) E receptor EP3 subtype were isolated from a human kidney cDNA library. Two cDNA clones differed only in their 3'-untranslated regions. The four isoforms, tentatively named EP3-I, EP3-II, EP3-III, and EP3-IV, which were generated by alternative mRNA splicing, had identical amino acid sequences except for their different carboxyl-terminal tails. Transfection experiments revealed that all the four isoforms show high binding affinities to PGE2, PGE1, and M&B28767, an EP3-specific agonist, whereas their downstream signaling pathways are divergent. M&B28767 increased cAMP concentrations in cells expressing EP3-II and EP3-IV, whereas it inhibited forskolin-induced cAMP accumulations in cells expressing all EP3 isoforms. M&B28767 also stimulated phosphoinositide turnover in cells expressing EP3-I and EP3-II. Northern blot analysis revealed that the EP3 gene is expressed in a wide variety of human tissues. The human EP3 mRNA was present most abundantly in the kidney, pancreas, and uterus. A substantial expression was also detected in the heart, liver, skeletal muscle, small intestine, colon, prostate, ovary, and testis. Furthermore, reverse transcription-polymerase chain reaction analysis demonstrated tissue-specific expressions of the five different EP3 mRNA species. The present study suggests the presence of the multiple systems of PGE2/EP3 isoforms and leads to the better understanding of its physiological and pathophysiological implications in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476918

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Contractile function of the cervix plays a role in normal and pathological pregnancy and parturition.

Authors:  Ourlad Alzeus G Tantengco; Ramkumar Menon
Journal:  Med Hypotheses       Date:  2020-10-07       Impact factor: 1.538

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Functional screening for G protein-coupled receptor targets of 14,15-epoxyeicosatrienoic acid.

Authors:  Xuehong Liu; Zu-Yuan Qian; Fuchun Xie; Wei Fan; Jonathan W Nelson; Xiangshu Xiao; Sanjiv Kaul; Anthony P Barnes; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-09-17       Impact factor: 3.072

Review 6.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

7.  Rostral Ventrolateral Medulla EP3 Receptor Mediates the Sympathoexcitatory and Pressor Effects of Prostaglandin E2 in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-29       Impact factor: 4.030

8.  Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.

Authors:  Y Shoji; M Takahashi; T Kitamura; K Watanabe; T Kawamori; T Maruyama; Y Sugimoto; M Negishi; S Narumiya; T Sugimura; K Wakabayashi
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

10.  Intermolecular cross-talk between the prostaglandin E2 receptor (EP)3 of subtype and thromboxane A(2) receptor signalling in human erythroleukaemic cells.

Authors:  Helen M Reid; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.